WO2000033887A3 - Procedes et formulations permettant de reduire des anticorps circulants - Google Patents

Procedes et formulations permettant de reduire des anticorps circulants Download PDF

Info

Publication number
WO2000033887A3
WO2000033887A3 PCT/US1999/029336 US9929336W WO0033887A3 WO 2000033887 A3 WO2000033887 A3 WO 2000033887A3 US 9929336 W US9929336 W US 9929336W WO 0033887 A3 WO0033887 A3 WO 0033887A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
reducing circulating
formulations
antibodies
circulating antibodies
Prior art date
Application number
PCT/US1999/029336
Other languages
English (en)
Other versions
WO2000033887A2 (fr
Inventor
Richard M Jack
David S Jones
Lin Yu
Steven B Engle
Original Assignee
Jolla Pharma
Richard M Jack
David S Jones
Lin Yu
Steven B Engle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Pharma, Richard M Jack, David S Jones, Lin Yu, Steven B Engle filed Critical Jolla Pharma
Priority to AU21735/00A priority Critical patent/AU2173500A/en
Priority to CA002353620A priority patent/CA2353620A1/fr
Priority to JP2000586377A priority patent/JP2002531531A/ja
Priority to EP99966115A priority patent/EP1135167A2/fr
Publication of WO2000033887A2 publication Critical patent/WO2000033887A2/fr
Publication of WO2000033887A3 publication Critical patent/WO2000033887A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés permettant de réduire la concentration d'anticorps circulant, et notamment des anticorps associés à des maladies. Ces méthodes consistent à administrer à un individu des quantités efficaces de supports présentant des épitopes. Dans d'autres modes de réalisation, l'invention concerne des procédés utilisant des supports présentant des épitopes et permettant de réduire la concentration d'anticorps en circulation.
PCT/US1999/029336 1998-12-08 1999-12-09 Procedes et formulations permettant de reduire des anticorps circulants WO2000033887A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU21735/00A AU2173500A (en) 1998-12-09 1999-12-09 Methods and formulations for reducing circulating antibodies
CA002353620A CA2353620A1 (fr) 1998-12-09 1999-12-09 Procedes et formulations permettant de reduire des anticorps circulants
JP2000586377A JP2002531531A (ja) 1998-12-09 1999-12-09 循環している抗体を減少させるための方法および処方物
EP99966115A EP1135167A2 (fr) 1998-12-09 1999-12-09 Procedes et formulations permettant de reduire des anticorps circulants

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45787598A 1998-12-08 1998-12-08
US11163998P 1998-12-09 1998-12-09
US60/111,639 1998-12-09
US45787599A 1999-12-08 1999-12-08
US09/457,875 1999-12-08

Publications (2)

Publication Number Publication Date
WO2000033887A2 WO2000033887A2 (fr) 2000-06-15
WO2000033887A3 true WO2000033887A3 (fr) 2000-08-17

Family

ID=26809097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/029336 WO2000033887A2 (fr) 1998-12-08 1999-12-09 Procedes et formulations permettant de reduire des anticorps circulants

Country Status (5)

Country Link
EP (1) EP1135167A2 (fr)
JP (1) JP2002531531A (fr)
AU (1) AU2173500A (fr)
CA (1) CA2353620A1 (fr)
WO (1) WO2000033887A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041813A2 (fr) 1999-11-28 2001-06-14 La Jolla Pharmaceutical Company Procedes de traitement de lupus sur la base de l'affinite aux anticorps et procedes de criblage et compositions associees
WO2006115509A2 (fr) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
CN106103461B (zh) 2014-03-13 2019-05-10 巴塞尔大学 结合抗髓鞘相关糖蛋白的IgM抗体的碳水化合物配体
AU2016323377B2 (en) 2015-09-16 2021-04-15 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715376A1 (fr) 2019-03-23 2020-09-30 Ablevia biotech GmbH Composé pour la prévention ou le traitement de la myasthénie grave
EP3715374A1 (fr) 2019-03-23 2020-09-30 Ablevia biotech GmbH Composé de séquestration d'anticorps indésirables chez un patient
EP3715375A1 (fr) 2019-03-23 2020-09-30 Ablevia biotech GmbH Composé pour la prévention ou le traitement de la pré-éclampsie
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
US20230355784A1 (en) 2020-09-23 2023-11-09 Ablevia Biotech Gmbh Compound for the prevention or treatment of autoantibody-mediated conditions
US20230381334A1 (en) 2020-09-23 2023-11-30 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
WO2022063892A1 (fr) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Composé pour augmenter l'efficacité de vecteurs viraux
JP2023542388A (ja) 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー 第ｖｉｉｉ因子補充療法の有効性を増加させるための化合物
WO2022063880A1 (fr) 2020-09-24 2022-03-31 Ablevia Biotech Gmbh Composé pour prévenir ou traiter la myasthénie grave
WO2023180502A1 (fr) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Composé pour augmentation de l'efficacité des virus oncolytiques

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003735A1 (fr) * 1991-08-23 1993-03-04 Alberta Research Council Procedes et compositions d'attenuation de rejet de xenogrephe induit par les anticorps chez les receveurs humains
WO1995007073A1 (fr) * 1993-09-08 1995-03-16 La Jolla Pharmaceutical Company Molecules plates-formes non polymeres a valence, chimiquement definies, et leur conjugues
US5782792A (en) * 1986-11-21 1998-07-21 Cypress Bioscience, Inc. Method for treatment of rheumatoid arthritis
WO1998047915A1 (fr) * 1997-04-18 1998-10-29 Novartis Ag Neoglycoproteines
WO1999052561A1 (fr) * 1998-04-15 1999-10-21 Baxter International Inc. Inhibition d'anticorps xenoreactifs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5782792A (en) * 1986-11-21 1998-07-21 Cypress Bioscience, Inc. Method for treatment of rheumatoid arthritis
WO1993003735A1 (fr) * 1991-08-23 1993-03-04 Alberta Research Council Procedes et compositions d'attenuation de rejet de xenogrephe induit par les anticorps chez les receveurs humains
WO1995007073A1 (fr) * 1993-09-08 1995-03-16 La Jolla Pharmaceutical Company Molecules plates-formes non polymeres a valence, chimiquement definies, et leur conjugues
WO1998047915A1 (fr) * 1997-04-18 1998-10-29 Novartis Ag Neoglycoproteines
WO1999052561A1 (fr) * 1998-04-15 1999-10-21 Baxter International Inc. Inhibition d'anticorps xenoreactifs

Also Published As

Publication number Publication date
AU2173500A (en) 2000-06-26
EP1135167A2 (fr) 2001-09-26
JP2002531531A (ja) 2002-09-24
WO2000033887A2 (fr) 2000-06-15
CA2353620A1 (fr) 2000-06-15

Similar Documents

Publication Publication Date Title
WO2000033887A3 (fr) Procedes et formulations permettant de reduire des anticorps circulants
WO2002080754A3 (fr) Methodes d'utilisation d'une annexine permettant de visualiser la mort cellulaire in vivo et de traiter des etats pathologiques
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
WO2006138418A3 (fr) Amelioration de la performance cognitive avec des activateurs de sirtuine
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
WO2004075865A3 (fr) Modulation selective d'une activite biologique induite par le recepteur tlr
HK1044543A1 (en) Beta-secretase enzyme compositions and methods.
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
AU2002360488A1 (en) Methods and devices for detection and therapy of atheromatous plaque
WO2003053997A3 (fr) Methodes permettant d'augmenter l'erythropoietine endogene (epo)
DE69907240T2 (de) Feste phytase-zusammensetzungen
WO2003057698A3 (fr) Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine
IL140710A0 (en) Pulmonary delivery of active agents
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
PL336983A1 (en) Compounds, their production and application as carriers of nucleic acids in cells
BG101892A (en) Sugar-modified cytostatics
MXPA02003232A (es) Composiciones y metodos para alternar la expresion de genes.
ZA985026B (en) Method for enhancing the activity of an enzyme.
ATE242630T1 (de) Beladene bakterienghosts als träger- und targetingvehikel
IL140667A0 (en) Compositions containing at least one active substance having an influence on the levels of lipids in the blood
IL148514A0 (en) Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU3828699A (en) Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitorsof the activation of the nuclear transcription factors nf-Kappa
ES2193105T3 (es) Caramelos duros de estabilidad mejorada al almacenaje.
GB9923858D0 (en) Antimicrobial compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2353620

Country of ref document: CA

Ref country code: CA

Ref document number: 2353620

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 586377

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 21735/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999966115

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999966115

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999966115

Country of ref document: EP